Education Knowledge Base
BPC 157 LPT White Paper
BPC-157 (Body Protection Compound) LPT™ White Paper
This material is provided for educational and informational purposes only to licensed health care professionals. This information is obtained from sources believed to be reliable, but its accuracy cannot be guaranteed. Herbs and other natural substances are very powerful and can occasionally cause dangerous allergic reactions in a small percentage of the population. Licensed health care professionals should rely on sound professional judgment when recommending herbs and natural medicines/compounds to specific individuals. Individual use of herbs and natural medicines should be supervised by an appropriate health care professional. The use of any specific product should always be in accordance with the manufacturer’s directions.
| Liposomal LPT™ chewable tabs provide a safe and more efficient way for the body to absorb targeted therapeutic compounds. LPT™ does not have stability problems that plague the liposomal industry – LPT™ are proven stable over time. |
BPC-157 USES:
- Supports Body protection / may accelerate healing
- Supports Sports/exercise recovery (NOT WADA APPROVED)
- Supports Musculoskeletal soft tissue healing (bone, teeth, tendons, ligaments, muscles)
- GUT supportive – gastric ulcers and gastrointestinal issues like IBS, leaky gut, and Crohn’s disease
- Inflammation support
- Skin supportive
- Supports Neuroprotection
- May Improve wound and injury healing
DOSAGES:
- BPC-157 – 250 mcg per LPT™
- Chew and swallow 2 tablets daily for 4-12 weeks
- May repeat regimen as often as needed.
What Is BPC-157?
BPC-157 (Body protection compound), is an endogenous, stable pentadecapeptide – 15 amino acids – first derived from gastric juices. In laboratory studies, synthetic BPC-157 is reported to accelerate the healing of wounds, injuries and tissues, including tendons, ligament, bone, teeth, muscle, skin and gastric mucosa.[i],[ii] Moreover, skeletal muscle injury models have suggested a beneficial effect not only for disturbances that occur as a result of direct trauma but also for systemic insults including hyperkalamia and hypermagnesia. Promisingly, there are few studies reporting any adverse reactions to the administration of BPC 157.
BPC-157 is poorly bioavailable orally. This is the reason for needing an effective liposomal tablet. BPC-157 as a liposomal tablet (LPT) fits this need.
Background Science
In animal and in-vitro studies, BPC-157 is reported to have the following properties:[iii],[iv],[v],[vi],[vii],[viii],[ix]
- Helps heal tissues – promotes microscopic regeneration; improves tissue granulation, fibroblast recruitment and collagen formation.[x],[xi]
- Potent angiomodulatory factor
- Modulates angiogenesis – increased when needed, decreased when needed[xii]
- Stimulates NO (nitric oxide) production
- Stimulates angiogenic cytokines VEGF, FGF and TGF-beta
- Induces F-actin formation in fibroblasts
- Upregulates anti-inflammatory gene transcription factor
- Downregulates TNF-alpha – anti-inflammatory
- Upregulates growth hormone (GH)
- Reported to improve cell survival under oxidative stress
- Increased fibroblast migration and dispersal
- BPC-157 increases the extent of phosphorylation of paxillin and FAK proteins without affecting the amounts produced
- Used in deep skin burns, corneal injuries injured muscle, tendon, ligament or bone (see below animal wound healing from alkalai burn[xiii])
– Influences serotonergic, dopaminergic, opioid and GABAergic systems
– Improves neural regeneration
– Decreases neuroinflammation
– Positive effects in spinal cord injury (lab animals)
– May help in depression and other behavioral disorders
– Ameliorates alcohol withdrawal symptoms and opposes alcohol intoxication
– Protects against amphetamine-induced behavioral changes
- Cardioprotective[xvii]
– May help regulate blood pressure
– Nitric oxide improvement
– BPC 157 rapidly and permanently counteracts the QTc prolongation induced by neuroleptics (such as haloperidol, fluphenazine, clozapine, olanzapine, quetiapine) and prokinetics
- Gastroprotective
- In laboratory studies, BPC-157 was reported to block long term side effects (NO collagen synthesis blockage) of corticosteroid injections, and also reported to counteract gastric side effects of NSAIDs and neuroleptics.[xx],[xxi]
There is a lack of human studies with using BPC-157, but many patient cases have reported that BPC-157 is a powerful tool to help heal wounds, treat soft tissue injury and heal GUT issues.
| Science has reported BPC-157 has significant oral in-vivo limitations that impair bioavailability including instability in gastric juices. How can we solve this? BPC-157 LIPOTABS |
What are Lipotabs?
Lipotabs are a novel way to deliver dietary supplements and peptides. Lipotabs are chewable liposomal tablets with high bioavailability and stability. Lipotabs ingredients are made into very small particles (generally 60-130nm vs. conventional liposomes at 100-300nm), allowing for a much smaller dosage of the ingredient to be administered for the desired effects, and decreasing any potential unwanted effects – so the smaller, the better! Lipotabs are also chewable, meaning some buccal absorption (bypasses hepatic metabolism), easier to swallow and can be taken without water of necessary. Lipotabs are manufactured to FDA approved pharmaceutical specifications with safe, non-toxic ingredients/excipients.
Why Lipotabs?
Liposomal LPT chewable tabs provide a safe and more efficient way for the body to absorb nutrients, peptides and other targeted therapeutic compounds. LPT does not have stability problems that plague the current liquid liposomal industry – LPTs are proven stable.
Liquid liposomal products have inherent stability issues. Issues with Liquid Liposomes on the Market include:
- Needs significant heat to produce – makes product unstable and decomposes active and inert ingredients in the final product
- Particles clump together to form larger and larger particle size
- Liquid liposomes reported to grow from 100nm size to 3000nm over a 30-day period[1]
- Larger particle size means less bioavailable
- Larger size also means increased potential for side-effects
LPT particles don’t require heat for production and don’t “clump” like liquid liposomes over time:
- Means Greater Bioavailability
- Greater Stability
- Superior Product
- Superior Results
- No toxic excipients
|
Lipotabs are safe, chewable, oral liposomal tablets manufactured using patented, small molecule technology to improve bioavailability and biological effects. |
Copyright © 2023 James B. LaValle, Natural Formulations All rights reserved.
No part of this material may be used or reproduced in any manner whatsoever, stored in a retrieval system, or transmitted in any form, or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior permission of the author.
This material is provided for educational and informational purposes only to licensed health care professionals. This information is obtained from sources believed to be reliable, but its accuracy cannot be guaranteed. Herbs and other natural substances are very powerful and can occasionally cause dangerous allergic reactions in a small percentage of the population. Licensed health care professionals should rely on sound professional judgment when recommending herbs and natural medicines/compounds to specific individuals. Individual use of herbs and natural medicines should be supervised by an appropriate health care professional. The use of any specific product should always be in accordance with the manufacturer’s directions.
[1] Lombardo D, Kiselev MA. Methods of Liposomes Preparation: Formation and Control Factors of Versatile Nanocarriers for Biomedical and Nanomedicine Application. Pharmaceutics. 2022;14(3):543.
[i] Duzel A, et al. stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: new insights. World J Gastroenterol. 2017;23:465–8488.
[ii] Gwyer D, et al. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):152-59.
[iii] Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2010; 110:774–780.
[iv] Hsieh MJ, et al. Therapeutic potential of proantiogenic BPC-157 is associated with VEGFR2 activation and up-regulation. J Mol Med. 2017;95(3):323-33.
[v]Sikiric P, et al. Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157. Vascular recruitment and gastrointestinal tract healing. Curr Pharm Des. 2018;24:1990–2001.
[vi] Ilic S, et al. Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions. Life Sci. 2011;88:535–542.
[vii] Stancic-Rokotov D, Slobodnjak Z, Aralica J, et al. Lung lesions and anti-ulcer agents beneficial effect: anti-ulcer agents pentadecapeptide BPC 157, ranitidine, omeprazole and atropine ameliorate lung lesion in rats. J Physiol Paris. 2001;95:303–308.
[viii] Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17:1612–1632.
[ix] Klicek R, Kolenc D, Suran J, et al. Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability. J Physiol Pharmacol. 2013;64:597–612.
[x] Duzel A, et al. Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfuction in rates: new insights. World J Gastroenterol. 2017;23(48):8465-88.
[xi] Chang CH, et al. Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts. Molecules. 2014;19(11):19066-077.
[xii] Seiwerth S, et al. BPC157 and blood vessels. Curr Pharm Des. 2014;20(7):1121-5.
[xiii] Huang T, et al. Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. Drug Des Devel Ther. 2015;9:2485-99.
[xiv] Sikiric P, et al. Brain-gut axis and pentadecapeptide BPC 157: Theoretical and practical implications. Curr Neuropharmacol. 2016;14:857-65.
[xv] Vukojevic J, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022;17(3):482-87.
[xvi] Jelovac N, et al. A novel pentadecapeptie, BPC-157, blocks the stereotypy producted acutely by amphetamine and the development of haloperidol-induced supersensitivity to amphetamine. Biol Psychiatr. 1998;43(7):511-9.
[xvii] Seiwerth S, et al. BPC157 and blood vessels. Curr Pharm Des, 2014;20(7):1121-35.
[xviii] Sikiric P, et al. Beneficial effect of a novel pendadecapeptide BPC157 on gastric lesions induced by restraint stress, ethanol, indomethacin, capsaicin neurotoxicity. Dig Dis Sci. 1996;41(8):1604-14.
[xix] Grgic T, et al. Stable gastric pentadecapeptide BPC 157 heals rat colovesical fistula. Eur J Pharmacol. 2016;780:1-7.
[xx] Drmic D, et al. Celecoxib-induced gastrointestinal liver and brain lesions in rats, counteraction by BPC157 or L-arginine, aggravation by L-NAME. W J Gastroenterol. 2017;23(29):5304-12.
[xxi] Jelovac N, et al. Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats. Eur J Pharmacol. 1999;379(1):19-31.